Your session is about to expire
← Back to Search
Other
Tinlarebant for Age-Related Macular Degeneration (PHOENIX Trial)
Phase 3
Recruiting
Research Sponsored by Belite Bio, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to month 24
Awards & highlights
PHOENIX Trial Summary
This trial will test if a new drug called tinlarebant is safe and effective in treating people with Geographic Atrophy (GA).
Who is the study for?
This trial is for individuals with confirmed diagnosis of Geographic Atrophy (GA), a form of age-related macular degeneration, who have a certain level of vision remaining. It's not open to those with diabetic eye diseases, advanced diabetic retinopathy, other retinal vascular diseases, or uncontrolled glaucoma in the study eye.Check my eligibility
What is being tested?
The trial is testing Tinlarebant against a placebo to see if it's safe and effective for treating GA. Participants are randomly assigned to receive either Tinlarebant or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While specific side effects for Tinlarebant aren't listed here, common side effects in trials like this may include irritation at the site of injection, headache, nausea, and potential allergic reactions.
PHOENIX Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to month 24
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to month 24
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size
Secondary outcome measures
To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT)
To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale
Other outcome measures
To evaluate the correlation between the reduction of serum RBP4 and the growth of atrophic lesions (DDAF)
To measure changes in contrast sensitivity as assessed using the Pelli-Robson Contrast Sensitivity Chart (or any assessment deemed acceptable by study sites)
To measure changes in retinal sensitivity as assessed by microperimetry
PHOENIX Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LBS-008, TinlarebantExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Age-Related Macular Degeneration (AMD) include anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina to prevent leakage and vision loss, and photodynamic therapy, which uses a photosensitizing agent and light to destroy these vessels. Emerging treatments like Tinlarebant (LBS-008) likely target similar pathways to prevent retinal damage.
Understanding these mechanisms is crucial for AMD patients to select the most appropriate treatment to slow disease progression and preserve vision.
Find a Location
Who is running the clinical trial?
Belite Bio, IncLead Sponsor
6 Previous Clinical Trials
303 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have swelling or disease in the central part of my retina due to diabetes.My eye condition is more severe than mild diabetic retinopathy.I have uncontrolled glaucoma in one of my eyes.I have been diagnosed with GA and have atrophic lesions in one or both eyes.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: LBS-008, Tinlarebant
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger